Recurrence Tumor Model Development Services

In oncology drug discovery, traditional efficacy assessments often focus only on the initial response of primary tumors, neglecting acquired resistance and residual disease recurrence. Alfa Cytology provides comprehensive recurrence tumor model development services, establishing stable acquired resistance and relapse models through sustained in vivo drug pressure for studies on resistance mechanisms, second-line therapy validation, and recurrence-suppressing combination screening.

Introduction to Recurrence Tumor Model

Recurrence tumor model development represents a paradigm shift in translational oncology. Unlike conventional preclinical models that assess only primary drug response, recurrence tumor models are derived from tumors that have been exposed to therapeutic pressure—either from patient post-relapse surgical specimens, biopsies, or from in vivo drug-pressured PDX/PDOX models. These models faithfully preserve the acquired resistance mechanisms, clonal architecture, and phenotypic adaptations (e.g., EMT, lineage switching, neuroendocrine differentiation) that emerge under drug selection pressure. They enable longitudinal tracking of clonal evolution, identification of resistance-driving mutations, and functional validation of second-line therapies in a clinically relevant context.

Fig. 1 A proliferation tracing and ablation system for modeling breast cancer relapse. (Wang X, et al.; 2025)

Applications of Recurrence Tumor Model

Our Services

Alfa Cytology provides a specialized recurrence tumor model development service designed to transform post-relapse patient specimens or drug-pressured models into clinically relevant platforms for studying resistance mechanisms and validating second-line therapies. Our models retain the acquired genetic alterations and phenotypic adaptations of recurrent tumors, ensuring authentic resistance profiles and high clinical relevance.

Through a workflow that establishes drug-pressured or patient-derived relapse models within 3 to 5 months, we enable longitudinal assessment of acquired resistance mechanisms and evaluation of recurrence-suppressing strategies. The resulting recurrence tumor model biobank offers the biological relevance and scalability required for precision oncology and translational research.

Workflow of Recurrence Tumor Model Development

Sample Acquisition

Receive post-relapse patient specimens (tissue, blood, or effusion) or generate drug-pressured models via continuous drug exposure.

Model Establishment

Establish patient-derived relapse models (PDX, organoids, or primary cultures) or drug-pressured relapse models. Preserve acquired genetic alterations and phenotypic adaptations.

Model Characterization

Validate resistance profiles via genomic, transcriptomic, and functional assays. Confirm clinical relevance against original patient specimens.

Model Expansion & Biobanking

Expand validated models to sufficient scale. Cryopreserve and maintain a curated recurrence tumor model biobank with annotated resistance metadata.

Downstream Applications

Conduct resistance mechanism studies, second-line therapy validation, recurrence-suppressing strategy evaluation, or precision oncology biomarker discovery.

Supported Cancer Types for Recurrence Tumor Model Development

Cancer Type	Resistance Mechanisms Modeled	Key Applications
Lung Cancer	EGFR T790M/C797S, ALK resistance, KRAS G12C secondary mutations, MET amp	TKI resistance, second-line therapy, combination strategies
Breast Cancer	CDK4/6 inhibitor resistance, ESR1 mutations, HER2 resistance, PARP inhibitor resistance	Endocrine resistance, targeted therapy resistance
Colorectal Cancer	Anti-EGFR resistance (KRAS/NRAS/BRAF mutations), FOLFOX/FOLFIRI chemoresistance	Chemo-resistance, targeted therapy resistance
Prostate Cancer	AR-V7, AR LBD mutations, neuroendocrine differentiation, enzalutamide resistance	Hormone resistance, lineage plasticity
Ovarian Cancer	Platinum resistance, BRCA reversion mutations, PARP inhibitor resistance	Chemoresistance, synthetic lethality
Melanoma	BRAF inhibitor resistance (MAPK reactivation, RTK upregulation)	Targeted therapy resistance
Other Supported Types	Gastric Cancer, Pancreatic Cancer, Bladder Cancer, Head & Neck Cancer, Hematologic Malignancies (upon request)

Alfa Cytology offers flexible recurrence tumor model development packages customized to your specific program needs—whether you require patient-derived relapse models from clinical specimens, drug-pressured acquired resistance models from established PDX/PDOX lines, matched pre-/post-treatment model pairs for comparative studies, or recurrence-suppressing combination screening. Our team of translational oncology and resistance biology specialists is ready to assist with resistance mechanism feasibility assessment, drug pressure optimization, and data interpretation. If you seek further exploration of recurrence tumor model development services for your oncology drug discovery programs, please feel free to contact us.

For research use only.